Drugs Made In America Acquisition II Corp. (DMII): Cash & Equivalents

Annual figures by period end, from SEC filings.

$223

As of 2025-12-31

$175.0K

As of 2026-06-30

Period ended	Cash & Equivalents	Change YoY	Source filing
2025-12-31	$223	n/a	2026-04-15, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Blank Checks), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cash & Equivalents	Change YoY
Drugs Made In America Acquisition II Corp. (DMII)	2025-12-31	$223	n/a
EQV Ventures Acquisition Corp. II (EVAC)	2025-12-31	$1.09M	n/a
Bain Capital GSS Investment Corp. (BCSS)	2025-12-31	$0	n/a
Cantor Equity Partners IV, Inc. (CEPF)	2025-12-31	$25.0K	n/a
Innventure, Inc. (INV)	2025-12-31	$60.45M	+443.7%
American Exceptionalism Acquisition Corp. A (AEXA)	2025-12-31	$0	n/a
Apex Treasury Corp (APXT)	2025-12-31	$991.5K	n/a
Berto Acquisition Corp. (TACO)	2025-12-31	$0	n/a
Velos Acquisition I Corp. (VLOS)	2025-12-31	$0	n/a

Compare DMII, EVAC, BCSS, CEPF side by side · Screen every company in Blank Checks ↗